US 12,252,520 B2
Myosin 15 promoters and uses thereof
Joseph Burns, Newton, MA (US); Kathryn Ellis, Arlington, MA (US); Adam Palermo, Somerville, MA (US); Martin Schwander, Auburndale, MA (US); Jonathon Whitton, Cambridge, MA (US); Leah Sabin, Goldens Bridge, NY (US); Christos Kyratsous, Irvington, NY (US); and Meghan Drummond Samuelson, Katonah, NY (US)
Assigned to Decibel Therapeutics, Inc., Boston, MA (US); and Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Decibel Therapeutics, Inc., Boston, MA (US); and Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Aug. 6, 2021, as Appl. No. 17/395,773.
Application 17/395,773 is a continuation of application No. PCT/US2020/017292, filed on Feb. 7, 2020.
Claims priority of provisional application 62/965,773, filed on Jan. 24, 2020.
Claims priority of provisional application 62/928,311, filed on Oct. 30, 2019.
Claims priority of provisional application 62/802,874, filed on Feb. 8, 2019.
Prior Publication US 2021/0388045 A1, Dec. 16, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01); C12N 15/86 (2006.01)
CPC C07K 14/4716 (2013.01) [A61K 48/0058 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2750/14143 (2013.01)] 13 Claims
 
1. A polynucleotide having at least 85% sequence identity to SEQ ID NO: 15.